Bayer EPS - Earnings per Share 2012-2025 | BAYRY
Bayer annual and quarterly earnings per share history from 2012 to 2025. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Bayer EPS for the quarter ending December 31, 2025 was $-1.05, a 342.69% decline year-over-year.
- Bayer EPS for the twelve months ending December 31, 2025 was $-1.04, a 48.08% increase year-over-year.
- Bayer 2025 annual EPS was $-1.04, a 48.08% increase from 2024.
- Bayer 2024 annual EPS was $-0.7, a 13.1% decline from 2023.
- Bayer 2023 annual EPS was $-0.81, a 172.75% decline from 2022.
| Bayer Annual EPS | |
|---|---|
| 2025 | $-1.04 |
| 2024 | $-0.70 |
| 2023 | $-0.81 |
| 2022 | $1.11 |
| 2021 | $0.30 |
| 2020 | $-3.05 |
| 2019 | $1.17 |
| 2018 | $0.53 |
| 2017 | $2.38 |
| 2016 | $1.51 |
| 2015 | $1.38 |
| 2014 | $1.38 |
| 2013 | $1.28 |
| 2012 | $0.95 |
| 2011 | $1.01 |
| Bayer Quarterly EPS | |
|---|---|
| 2025-12-31 | $-1.05 |
| 2025-09-30 | $-0.29 |
| 2025-06-30 | $-0.06 |
| 2025-03-31 | $0.35 |
| 2024-12-31 | $0.43 |
| 2024-09-30 | $-1.17 |
| 2024-06-30 | $-0.52 |
| 2024-03-31 | $0.55 |
| 2023-12-31 | $0.39 |
| 2023-09-30 | $-1.27 |
| 2023-06-30 | $-0.52 |
| 2023-03-31 | $0.60 |
| 2022-12-31 | $0.11 |
| 2022-09-30 | $0.14 |
| 2022-06-30 | $-0.08 |
| 2022-03-31 | $0.94 |
| 2021-12-31 | $0.35 |
| 2021-09-30 | $0.03 |
| 2021-06-30 | $-0.72 |
| 2021-03-31 | $0.64 |
| 2020-12-31 | $0.02 |
| 2020-09-30 | $-0.82 |
| 2020-06-30 | $-2.68 |
| 2020-03-31 | $0.42 |
| 2019-12-31 | $0.43 |
| 2019-09-30 | $0.26 |
| 2019-06-30 | $0.12 |
| 2019-03-31 | $0.36 |
| 2018-12-31 | $-1.27 |
| 2018-09-30 | $0.86 |
| 2018-06-30 | $0.26 |
| 2018-03-31 | $0.69 |
| 2017-12-31 | $0.20 |
| 2017-09-30 | $1.31 |
| 2017-06-30 | $0.39 |
| 2017-03-31 | $0.49 |
| 2016-12-31 | $0.13 |
| 2016-09-30 | $0.40 |
| 2016-06-30 | $0.47 |
| 2016-03-31 | $0.51 |
| 2015-12-31 | $0.21 |
| 2015-09-30 | $0.34 |
| 2015-06-30 | $0.39 |
| 2015-03-31 | $0.45 |
| 2014-12-31 | $0.06 |
| 2014-09-30 | $0.33 |
| 2014-06-30 | $0.39 |
| 2014-03-31 | $0.59 |
| 2013-12-31 | $0.19 |
| 2013-09-30 | $0.30 |
| 2013-06-30 | $0.33 |
| 2013-03-31 | $0.46 |
| 2012-12-31 | $0.14 |
| 2012-09-30 | $0.20 |
| 2012-06-30 | $0.19 |
| 2012-03-31 | $0.42 |
| 2011-12-31 | $0.16 |
| 2011-09-30 | $0.28 |
| 2011-06-30 | $0.33 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $46.178B | $51.552B |
| Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |